Skip to main content
. 2015 Oct 8;6(35):37782–37791. doi: 10.18632/oncotarget.5622

Figure 3. Systemic R11-p53C peptide administration inhibited orthotopical tumor growth.

Figure 3

A–B. T24 orthotopical tumor growth after R11-p53C treatment. T24-luc cells were instilled into the bladder to develop a superficial bladder cancer model (n = 6/group) at Day 0 and randomized to receive 200 μl of peptides and control twice a week and repeated 3 weeks. Tumor growth was determined. C. The survival curves were determined in every group. *P < 0.05. D. Representative pictures of p21 and Ki-67 IHC staining in T24 orthotopical xenograft tissues with or without R11-p53C treatment. The scale bar represents 100 μm. Quantification analyses of IHC score were shown (right panel).